Anna Johansson on Tue, 12 Nov 2002 22:06:01 +0100 (CET)

[Date Prev] [Date Next] [Thread Prev] [Thread Next] [Date Index] [Thread Index]

[Nettime-bold] BSG BioNewsLetter - Ion Channel Targets - Antifungals - 07#2002

BSG BioNewsLetter 07#2002 - BioSeeker Group's analysis and products eNewsletter



1) Back to the Future - New Optimism in Ion Channel Drug Discovery
2) New Report: 'Ion Channels as Therapeutic Targets for Multiple Diseases'
3) New Report: 'New Targets and Drug Discovery Platforms in Antifungal R&D'
4) Announcement of World-Wide Company Information through BioSeeker Group's Website
5) Conference Opportunity - BioBusiness 2003
6) Coming reports: HCV Therapy / Winning the Osteoporosis Therapy Race
7) Recently Published Reports
8) Subscription
9) BioSeeker Online Store



Why is it worth spending money on ion channel drug discovery? There are several other therapeutic targets that potentially cover most disease groups and research technologies used to investigate effects on ion channels are relatively expensive and difficult to handle. There are several answers to the question. One major factor is that these transporters are relatively untouched ground. Since the vast physiological importance of ion channels for many cellular and tissue functions, in combination with their, in many cases, specific genetic expression patterns make them highly interesting for drug targeting. 

Read the full version of this free, analytical BioNewsletter article at


   - A New Report from BioSeeker Group

Several disease states are related to dysfunctional ion channels. Among prominent groups are cardiac arrhythmias, diabetes, hypertension, angina pectoris and epilepsy. Several drugs already marketed have generated substantial revenues for the companies. Already today, drugs targeting ion channels generates over 6 billion dollars in sales per annum. BioSeeker Group AB has recognized the interest and need for a continuous surveillance within the field of ion channels as targets for drug discovery. This report includes market outlooks and updated information on ion channel targets related to diseases such as urinary incontinence, multiple sclerosis, diabetes, inflammation, pain and CNS disorders such as epilepsy and depression. Scientific advancements are presented in relation to each disease group. Further, the report comments on new ion channel drug discovery technologies.

For more information about this report, please visit


   - A New Report from BioSeeker Group

According to the Antifungal Work Group at NIH there is a "critical need for the development of antifungal agents". The urgency stems from the therapeutic limitations of the present antifungal compounds development of fungal drug resistant, drug-related toxicity, hazardous drug-drug interactions and non-optimal pharmacokinetics. This makes them inadequate in prophylactic treatments for immuno-compromised patients. The wish for a safe prophylactic antifungal therapy may not be far away from being realized and a success would certainly provide substantial revenues.

In this report, we provide an overview and assessment of emerging drug targets and screening assays. We place special emphasis on glycosylphosphatidylinositol (GPI) anchoring, ABC phospholipid translocators, elongation factor-2 and calcineurin. Extensive scientific research is conducted in these areas and important breakthrough are expected earlier than for other novel targets. 

For more information about this report, please visit



BioSeeker Groups intelligence is further enhanced by strategic use of SkyMinder, a one-stop shopping tool for business information from thousands of the best quality information sources all over the world. To give the very best to our readers of the BSG BioNewsletter we have asked SkyMinder to highlight their capabilities in providing world wide company information on biotechnology and pharmaceutical industry through our website This service will be available from the 20th of November 2002. 



BioBusiness 2003 is the premier bio-partnering event for biotech and pharma business development and licensing executives. At this senior-levelinternational event you won't have to trawl through your 200 fellow attendees to find fellow business development and licensing professionals as these are the only biotech and pharma representatives coming!  So instead of wasting your time looking for them, you can concentrate on discussing strategies with them in interactive roundtable groups or formulating future plans with them in private one-to-one meetings. Plus you can learn from the best!  Hear from 16 leading pharmaceuticals and 15 world class biotechs, such as Novartis, F. Hoffman La Roche, Boehringer Ingelheim, Aventis, Genentech, Genzyme and Vertex Pharmaceuticals, who will tell you what they are currently looking for in business partners and how they see alliance and partnering strategies developing in the next five years. Book your place now! 

For more information, please visit  or contact Colin Chapman (



- Complete Guide to Molecular Approaches for HCV Therapy

Treatment of HCV (Hepatitis C Virus) is a market with unmet medical needs, with relatively young people infected and a high risk for chronic disease. The coming decade will see exciting developments in HCV therapy thanks to breakthroughs in overcoming a major barrier to development: the lack of dedicated models suitable for validating candidate compounds in a low-cost, highthroughput format. BioSeeker Group has identified at least 115 companies with interest in various stages in the field of HCV therapy. Out of these 100, approximately 10 of the 'big pharma' are represented. Our coming report "Complete Guide to Molecular Approaches for HCV Therapy" analyses the field of new HCV therapeutics and assess possible outcomes for drugs and companies in this sector. 

Please contact us at for more information about this report.For further reading about HCV, please visit our free analytical article on this topic (

- Winning the Osteoporosis Therapy Race

Osteoporosis, deterioration of bone tissue and an increased risk of fractures, is considered by the World Health Organization to be second only to cardiovascular disease as a leading healthcare problem. According to other studies, sales of osteoporosis drugs in these markets totaled $3.4 billion in 2000, and are expected to reach $6.5 billion by 2005. A new class of osteoporosis therapies, designed to build bone mass in contrast to currently available anti-osteoporosis medicines are presently under study. These anabolic therapies consist of parathyroid hormone (Forto and ALX-11) or fluoride to stimulate bone formation, but their safety and efficacy remain to be established. The first of these drugs to reach the market will probably be Forto, known generically as teriparatide (recombinant parathyroid hormone).

Please contact us for more information about this report ( For further reading about osteoporosis, please visit our free analytical article on this topic (



- Swedish Biopharma Industry - The Next Wave (released Sept, 2002)

- Ion Channel Assays in the Drug Discovery Process (released June, 2002)

- The Competitive Landscape of Cancer Gene Therapy (released May, 2002)

- Commercializing on Tumor Antigens: Analytical Perspectives (released Feb, 2002)



To continue to stay tuned with coming editions of BioSeeker Groups BioNewsLetter, please send an email to



BioSeeker has now made it easy to order any of our products online, directly from our website. Visit  to place an online order.


Do you have a message that you would like the biotech community to know? BioSeeker Group's Newsletter targets managers, scientists, venture capitalists, consultants and many more world wide. Contact us at for further information on how to advertise in BSG BioNewsletter.


If you would like to comment on our newsletter please send us an email to

If you would like to be removed from our newsletter list, please reply to

Nettime-bold mailing list